3 Reasons to Buy Novavax and 1 to Sell

Novavax (NASDAQ: NVAX) is a pandemic stock. That's why it soared in 2020-21 when the world faced the worst pandemic since the influenza outbreak of 1918. When COVID-19 hit, this vaccine biotech made an almost impossible run, from a low of $4 a share all the way to $330.

Now it's down to $50, and the company's market cap is under $4 billion. Is it a buy at these prices? Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.

Image source: Getty Images.

Source Fool.com